The Mayne Pharma Group Ltd (ASX: MYX) share price is climbing today after revealing its E4/DRSP drug is one step closer to commercialisation.

At the time of writing, Mayne Pharma shares have jumped 4.6% to 38.7 cents after rallying as much as 8.1% in morning trade.

What did Mayne Pharma announce?

This morning, Mayne Pharma revealed the new drug application (NDA) for E4/DRSP to prevent pregnancy has been accepted for review by the US Food and Drug Administration (FDA).

The NDA submission includes results from two phase 3 clinical studies conducted in more than 3,725 women aged 16 to 50.

E4/DRSP is a novel combined contraceptive pill that contains 15mg of estetrol (E4) and 3mg of drospirenone (DRSP). 

The drug is being developed by strategic partner Mithra Pharmaceuticals SA, a biotech based in Belgium.

Mayne signed a 20-year exclusive supply and license agreement with Mithra in October 2019 to commercialise E4/DRSP in the US. This was followed by a similar agreement for the Australian market announced in May.

What is the market opportunity for E4/DRSP?

If approved, E4/DRSP would be the first contraceptive product containing E4. It would also be the first new estrogen introduced in the US for contraceptive use in approximately 50 years.

Mayne believes the US contraceptive market is valued at US$5.4 billion. The short acting combined hormonal oral contraceptives component of the market is estimated at US$4 billion, with approximately 135 million units sold annually.

Meanwhile, Mayne states that the Australian contraceptive market is valued at $130 million, with approximately 14 million short acting combined hormonal oral contraceptives sold annually.

Management commentary

Commenting on today’s update, chief executive Scott Richards said:

“This is another important milestone for E4/DRSP and brings us one step closer to providing women in the US with a new contraceptive that we believe will be effective, safe and well-tolerated. We look forward to working with the FDA and Mithra during the ongoing review of our application.” 

“In parallel, we continue to advance our US commercial strategy and infrastructure to ensure we are well positioned to support the potential launch of E4/DRSP in the first half of calendar 2021,” Mr Richards added.

Mayne has plans to file E4/DRSP with the Australian Therapeutic Goods Administration this calendar year.

More reading

• These 5 ASX shares saw the biggest losses last week
• ASX 200 Weekly Wrap: ASX back in the green
• These were the worst performers on the ASX 200 last week
• ASX 200 finishes higher by 0.8%, Carsales share price driven up by FY20 guidance
• ASX 200 down 0.1%: Carsales update impresses, a2 Milk surges higher

Motley Fool contributor Cathryn Goh has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why the Mayne Pharma share price is climbing today appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/37U30GK

I am particularly attracted to ASX healthcare shares right now. The world’s growing and ageing population is driving an ever-increasing demand for healthcare services.

Here we take a close look at 3 of my top ASX healthcare share picks in CSL Limited (ASX: CSL), Ramsay Health Care Limited (ASX: RHC) and ResMed Inc (ASX: RMD).

All 3 have evolved to become global leaders in their respective healthcare segments.

CSL

CSL has grown from strength to strength over the past 3 decades.

It has evolved from a very small federal government department to become one of, if not the largest company on the ASX. It currently has a market capitalization of $132.5 billion.

The company is now a global market leader in blood plasma research and disease treatment. It has an impressive global product reach spanning more than 60 countries.

CSL has also become a world leader in the quest to find an effective treatment for the coronavirus. It has recently entered into an agreement to ramp up the development of a COVID-19 vaccine candidate.

I believe that CSL is well-positioned to continue growing its revenue base strongly over the next 5–10 years. A strong new product development pipeline will drive this growth.  

Ramsay

Another ASX healthcare company I would consider buying right now is Ramsay. Like CSL, it also has evolved significantly over the past few decades. It is now Australia’s largest private healthcare provider. Ramsay operates in 11 other countries including the United Kingdom, France, Indonesia, Malaysia and Italy.

Its global scale enables the company to spread its operating costs. It also gives Ramsay a competitive advantage over its smaller rivals in negotiations with health provider insurance companies.

A pause on some elective surgeries during the early phase of the coronavirus pandemic saw Ramsay’s share price impacted. However, these bans are gradually being lifted.

Ramsay has also successfully signed a number of key government deals in Australia and the United Kingdom during the pandemic.

ResMed

ResMed has also grown modest origins to become a leading global healthcare operator in its market niche.

This ASX company manufactures devices and cloud-based software solutions for the treatment of sleep apnoea as well as other chronic respiratory illnesses.

ResMed continues to grow its revenue base strongly. It achieved an impressive 47% increase in net income during Q3 FY20.

I see a strong demand for ResMed’s products continuing well into the next decade. It is estimated that around 1 billion people are impacted by sleep apnoea worldwide, while more than 80% of cases are undiagnosed globally.

More reading

• Invest like Warren Buffett by buying and holding these ASX 200 shares
• 3 quality ASX growth shares to buy and hold
• Where to invest $20,000 into ASX shares immediately
• ASX 200 Weekly Wrap: ASX back in the green
• These fantastic healthcare ASX shares could make you wealthy

Phil Harpur owns shares of CSL Ltd. and ResMed Inc. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has recommended Ramsay Health Care Limited and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Consider these 3 quality ASX healthcare shares to buy now appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2B3tZ6M

If you’re just starting out with investing, I wouldn’t worry if you don’t have tens of thousands of dollars to invest. Even if you only have $5,000 to invest each year, you can still generate material wealth if you do it consistently and think long term.

According to research by Fidelity, the Australian share market has generated an average total return of ~9.2% per annum over the last three decades. Based on this, if you invested $5,000 each year for the last 30 years (and earned the market return), your portfolio would now be valued at a massive ~$773,000.

Overall, I believe this shows just how rewarding it can be to make regular investments over a long period.

But which shares should you buy with your first $5,000? Two ASX shares that I think could provide market-beating returns over the long term are listed below:

Afterpay Ltd (ASX: APT)

Although it is a reasonably high risk option because of its lofty valuation, I still believe Afterpay could be a great long term investment. I believe the buy now pay later provider is well-positioned for growth over the next decade and beyond thanks to the growing popularity of the payment method with consumers and merchants and its massive market opportunity in the United States.

In addition to this, I believe the company is very likely to expand into new territories in the near future. I suspect mainland Europe could come first and then probably the Asian market with the support of its substantial shareholder, WeChat. If it makes a success of these expansions, then Afterpay could become a payments giant in the future.

Altium Limited (ASX: ALU)

I think it is fair to say that 2020 has been a disappointing year for Altium. Unfortunately, it is one of the few tech companies which have been negatively impacted by the pandemic. Nevertheless, I believe this is a short term headwind and expect its growth to accelerate again in FY 2021.

Especially given how it is exposed to the growing Internet of Things (IoT) market. According to a company presentation, global technology spending on IoT is expected to reach US$1.2 trillion in 2022. Given that the vast majority of IoT devices have printed circuit boards inside them, this should lead to strong demand for its award-winning electronic design software.

More reading

• ASX 200 down 0.2%: Afterpay hits record high, TPG Telecom merger vote
• Why Afterpay, APA, Evolution, & Sonic shares are storming higher
• Coronavirus second wave potential could drive investment portfolio changes
• Best growth shares to buy with $4,000
• 5 things to watch on the ASX 200 on Wednesday

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Altium. The Motley Fool Australia owns shares of AFTERPAY T FPO. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post How to get rich by investing in ASX shares appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2B77FJk

At lunch on Wednesday the S&P/ASX 200 Index (ASX: XJO) has given back its morning gains and has dropped lower. The benchmark index is down 0.2% to 5,943.8 points.

Here’s what has been happening on the market today:

Afterpay hits record high on UK update.

The Afterpay Ltd (ASX: APT) share price jumped to a record high of $62.33 this morning. This follows the release of an announcement by the payments company after the market close on Tuesday. The announcement revealed that Afterpay’s UK-based Clearpay business now has over 1 million active customers on its platform after a year in the country. Management also notes that consumers are using its platform more frequently than they were in the U.S. at the same stage.

Sonic Healthcare update.

The Sonic Healthcare Limited (ASX: SHL) share price is storming higher on Wednesday after the release of a trading update. That update reveals that after the pandemic hit the healthcare company hard in March and April, its business has bounced back strongly in May and June. As a result of this, the company has reinstated its guidance and advised that it expects its EBITDA to be broadly flat in FY 2020.

TPG Telecom scheme meeting.

The TPG Telecom Ltd (ASX: TPM) share price is pushing higher on Wednesday after shareholders voted overwhelmingly in favour of its merger with Vodafone Australia. According to the AFR, 99.68% of proxies voted in favour of the deal. This means the companies could complete the mega merger on July 13.

Best and worst ASX 200 shares.

The best performer on the ASX 200 on Wednesday has been the Perseus Mining Limited (ASX: PRU) share price with a sizeable 8% gain. This follows a jump in the gold price overnight. The worst performer on the ASX 200 has been the Viva Energy Group Ltd (ASX: VEA) share price with a 4% decline. This is despite there being no news out of the fuel retailer.

More reading

• How to get rich by investing in ASX shares
• Is the Woolworths share price a secret buy?
• Alphabet soup: Is the ASX 200 in for a V-shaped COVID recovery or rolling Ws?
• Where to invest $10,000 in ASX 200 shares for 2030
• Ready to invest $5,000? I’d buy these ASX dividend shares today

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of AFTERPAY T FPO. The Motley Fool Australia has recommended Sonic Healthcare Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post ASX 200 down 0.2%: Afterpay hits record high, TPG Telecom merger vote appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2Noo4f1

The Woolworths Group Ltd (ASX: WOW) share price edged 0.8% lower yesterday, but is the Aussie retailer in the buy zone?

Why the Woolworths share price could be a secret buy

One thing that caught my interest yesterday was a trading update by SCA Property Group (ASX: SCP). 

SCA reported that sales performance for a number of its tenants had been volatile due to the coronavirus pandemic.

However, anchor tenants, such as supermarkets, have seen strong moving annual turnover (MAT) as at 31 May 2020.

In fact, SCA’s supermarket tenants increased year-on-year MAT by 4.4% through to 31 May.

I think this could be a good indicator of Woolworths’ performance so far given its dominance in the supermarket space.

Because the Woolworths share price is up just 0.7% for the year, it may be undervalued right now.

For context, the Coles Group Ltd (ASX: COL) share price is up 11.5% in 2020 while the S&P/ASX 200 Index (ASX: XJO) is down 10.95%.

This means that the Woolworths share price is underperforming its rival but outperforming the ASX 200 benchmark.

However, Woolworths is more of a conglomerate when compared to Coles’ singular supermarket focus.

One particular drag in 2020 has been Woolworths’ pubs business, ALH Group.

Tight restrictions on the hospitality sector have hurt earnings from ALH this year. However, as restrictions ease, the group could prove to become more of an asset to the Woolworths share price.

If supermarket turnover continues to climb, combined with increased pubs revenue, this could spark the Woolies share price to climb in 2020.

Foolish takeaway

The Woolworths share price is roughly unchanged from where it started the year. 

However, the positive update from SCA Property yesterday has got me thinking about whether it’s undervalued.

Given the strong momentum behind ASX shares since the March bear market, I think Woolworths could be heading higher before the end of the year.

More reading

• ASX 200 down 0.2%: Afterpay hits record high, TPG Telecom merger vote
• Alphabet soup: Is the ASX 200 in for a V-shaped COVID recovery or rolling Ws?
• Where to invest $10,000 in ASX 200 shares for 2030
• Ready to invest $5,000? I’d buy these ASX dividend shares today
• Leading broker tips the Coles share price to storm higher from here

Motley Fool contributor Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of COLESGROUP DEF SET, Wesfarmers Limited, and Woolworths Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Is the Woolworths share price a secret buy? appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2YshlHr

A V-shaped market recovery following COVID-19 is less likely than “rolling Ws”, says Liz Ann Sonders, Chief Investment Strategist at Charles Schwab.

Sonders recently shared her thoughts on the COVID-19 market performance and outlook via an article on the Charles Schwab website. 

Disconnect between the share market and economy  

Sonders stated that the No. 1 question she is fielding lately relates to the “disconnect between the stock market and the economy.” 

Certainly, the disconnect is present in the Australian share market too, with the Australian Financial Review (AFR) reporting on 3 June that the ASX 200 remained “unfazed by recession talk as it hit a three-month high.” 

The market participants’ rose-tinted outlook prompted JPMorgan Asset Management’s Global Market Strategist, Kerry Craig to infer that, “if the economic data remains weak for the moment, markets are likely to continue to discount that as being backward looking.” 

However, Craig identified a risk; that markets are “pricing in a lot of good news that might not materialise in the second half of the year.” 

Indeed, the S&P/ASX 200 Index (INDEXASX: XJO) is currently trading largely flat, with Victoria reinstating certain restrictions amid second-wave fears. 

Related to Craig’s worry, Sonders stated that second half will grant: “clarity on the depth of the economic contraction via both the second quarter earnings season… and the initial read on second quarter real gross domestic product.”  

The upcoming earnings season and updated gross domestic product figures may very well send the markets on a W-shaped rollercoaster. 

Shares lead the economy

Investigating recession data post-Second World War, Sonders found that, with the exception of 2001, “the stock market’s peaks and troughs have pre-dated the economy’s peaks and troughs.” 

Sonders further stated that there is a “fairly consistent history of the stock market’s peaks and troughs coming at or before the peaks and troughs in the economy.” 

This, for Sonders, confirms the view that “the stock market is a leading economic indicator.” 

Sonders also mused that she will closely monitor investor sentiment, “near-term market peaks and troughs are often defined more by investor emotions than economic data.” 

Takeaways for ASX 200 

NAB’s own CEO, Ross McEwan echoed Sonders’s thoughts on the shape of the recovery, with the AFR releasing an article titled: “McEwan backs more stimulus, tips W-shaped recovery.” 

A W-shaped recovery will require a more circumspect investing approach and a sturdy constitution to handle the likely-lively ride ahead. 

In an important caveat, JPMorgan’s Kerry Craig offered the following:

“If we’re heading for weaker growth and lower inflation, investors need to look for companies that can protect margins long-term, hence security selection is more important right now than the top down macro narrative.”

Sonders herself concluded that “the stock market probably got a bit ahead of itself in pricing in a V-shaped recovery.”

The positive news about flattened curves across the globe and encouraging headlines regarding vaccines may have spurred the V-shape recovery thesis. 

Therefore, Sonders thinks that “stocks may continue to be at the mercy of virus-related news — in both directions.”

More reading

• Where to invest $10,000 in ASX 200 shares for 2030
• Ready to invest $5,000? I’d buy these ASX dividend shares today
• 5 things to watch on the ASX 200 on Wednesday
• ASX 200 finishes higher, Woolworths gives update
• Invest like Warren Buffett by buying and holding these ASX 200 shares

Motley Fool contributor Kiryll Prakapenka has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Alphabet soup: Is the ASX 200 in for a V-shaped COVID recovery or rolling Ws? appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/3dtpjEj

2020 has been a crazy ride for many ASX 200 share investors.

The S&P/ASX 200 Index (ASX: XJO) is down 10.6% in 2020 thanks largely to the steep bear market over February and March. 

It’s true that investing in the share market isn’t for everyone. There are a lot of factors that should be considered before diving into ASX 200 shares and one of them is time.

I believe if you’re not investing for at least the next 7 to 10 years, it may not be wise to buy right now.

But if you’re looking to invest for the next decade or more, here are a few shares I would buy with $10,000 today.

Where to invest $10,000 in ASX 200 shares for 2030

I like a couple of blue-chip shares in the current market.

The first one I’m looking at right now is Fortescue Metals Group Limited (ASX: FMG).

The Fortescue share price is up 32.7% this year and more than 600% in the last 5 years.

The Aussie iron ore miner could be set for a big decade of growth in the 2020s. I think a strong relationship with China and growing sales to India could be the key to success for Fortescue in the decade ahead.

Combine this with a potential infrastructure boom in the short to medium-term, and Fortescue is one ASX 200 share definitely worth watching right now.

A2 Milk Company Ltd (ASX: A2M) is another ASX blue-chip on my radar.

Just like Fortescue, this dual listed dairy share has seen strong growth over recent years. In fact, the A2 Milk share price has rocketed 26% higher in 2020 alone.

A2 Milk is looking to expand internationally and not just throughout Asia. On top of the lucrative Chinese market, the company is looking to establish a foothold with the brand in Canada.

If A2 Milk can execute on its strategy over the next 10 years, I think it could be worth much more than its current $13.4 billion valuation.

But, it’s not only the blue-chips that I’ve got my eye on. I also like the look of ASX 200 growth shares like Xero Limited (ASX: XRO).

Xero is a leading accounting software provider that targets small and medium enterprises (SMEs). More innovation and a rise in small business participation could be a good thing for Xero sales in the coming years.

If Xero can continue its market domination, then who knows where this Aussie tech share’s price will be in 10 years’ time.

More reading

• Alphabet soup: Is the ASX 200 in for a V-shaped COVID recovery or rolling Ws?
• Ready to invest $5,000? I’d buy these ASX dividend shares today
• How ASX 200 shares like Xero could help you retire early
• Best growth shares to buy with $4,000
• 5 things to watch on the ASX 200 on Wednesday

Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Xero. The Motley Fool Australia owns shares of A2 Milk. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Where to invest $10,000 in ASX 200 shares for 2030 appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2Nn720K

You might be eyeing the current market as an opportunity to buy some cheap ASX dividend shares.

The S&P/ASX 200 Index (ASX: XJO) is down 10.5% since the start of the year, which could mean there are some bargain buys.

However, I think it’s easier said than done to find undervalued shares. There are a lot of smart investors out there hunting for bargains.

Here are a few of the ASX dividend shares that I would consider investing in today.

Why Telstra is on my ASX dividend share watchlist

I think Telstra Corporation Ltd (ASX: TLS) shares are worth a look right now.

Telstra has been an ASX dividend share staple for a number of years now, although it’s true that there have been some steep share price declines and dividend cuts to Telstra shares in recent years.

That means the Aussie telco may not be the reliable income share it has been in the past, but I still think there could be some long-term value. Telstra is currently yielding 3.1%, which would be a handy portfolio boost in the current times.

Of course, dividend yields could be misleading right now, but I think Telstra’s future dividend payment prospects remain bright, particularly given its emerging position as a potential leader in the 5G network space. That could be the key to the Aussie telco gaining back market share (and earnings) it has lost to the NBN.

Are ASX bank shares worth a look?

Out of the ASX banks, I think Macquarie Group Ltd (ASX: MQG) could be a solid ASX dividend share to buy.

The Macquarie share price is down 11.8% this year and in my opinion could be an undervalued prospect, given its 3.5% dividend yield. Recent ASX bank dividend cuts don’t bode well for strong income in 2020, but there’s a chance Macquarie could maintain its distributions.

If Macquarie’s investment teams can capitalise on the current market volatility, that could pave the way for a strong half-year earnings result. Higher earnings often means more free cash flow, which is good news for investors holding out hope for half-year dividend payment.

Can this ASX dividend share outperform in 2020?

JB Hi-Fi Limited (ASX: JBH) is one ASX dividend share, in particular, that I think could outperform in the next 12 months.

The JB Hi-Fi share price is up 10% in 2020 but it could be set to climb higher if it continues its strong sales trajectory.

More Aussies working from home has been a big factor behind the recent share price move.

JB Hi-Fi’s electronics sales have skyrocketed in recent months but I think there’s more potential growth on the way. If we see a sustained shift towards a more remote working model, that could see more Aussies upgrade their home setups.

It’s certainly not a long-term trend, but any short-term sales boost is welcome in the current market. More sales means higher earnings and that could mean JB Hi-Fi maintains its distributions, while other top companies are forced to make cuts.

That would be good news for JB Hi-Fi and its investors, who could pick up a 3.6% dividend yield today.

Foolish takeaway

These are just a few of the ASX dividend shares that I think could be good value buys for income alongside some potential capital gains.

More reading

• Alphabet soup: Is the ASX 200 in for a V-shaped COVID recovery or rolling Ws?
• Where to invest $10,000 in ASX 200 shares for 2030
• Why I think the Telstra share price could hit $4 in 2020
• Is the Macquarie share price a buy?
• 5 things to watch on the ASX 200 on Wednesday

Motley Fool contributor Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Macquarie Group Limited and Telstra Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Ready to invest $5,000? I’d buy these ASX dividend shares today appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2zXlvxs

The S&P/ASX 200 Index (ASX: XJO) is on form again on Wednesday and on course to record a decent gain. At the time of writing the benchmark index is up almost 0.4% to 5,976.7 points.

Four shares that are climbing more than most today are listed below. Here’s why they are storming higher:

The Afterpay Ltd (ASX: APT) share price is up 3% to $60.93. Investors have been buying the payments company’s shares after it released an update on its UK business. According to the update, the Clearpay business has reached 1 million active customers after one year of operation in the country. Pleasingly, management notes that UK customers are using its service more frequently than its US customers were after one year in that market.

The APA Group (ASX: APA) share price has risen over 2.5% to $11.59. Investors have been buying the energy company’s shares after it revealed its distribution plans. APA announced an estimated final distribution of 27 cents per security for the second half. This brings its full year distribution to 50 cents per security, up 6.4% on FY 2019’s payout.

The Evolution Mining Ltd (ASX: EVN) share price has jumped 4% to $5.48. Investors have been buying the gold miner’s shares today after the gold price hit its highest level since late in 2012. Evolution is just one of a number of gold miners charging higher. So much so, the S&P/ASX All Ordinaries Gold index is up 2.5% at the time of writing.

The Sonic Healthcare Limited (ASX: SHL) share price has climbed almost 4% to $30.03. Investors have been buying the healthcare company’s shares after it released a trading update. That update revealed that its performance rebounded strongly in May and June following weakness in March and April. As a result, management revealed that it is in a position to provide guidance again. It now expects its EBITDA to be broadly flat in FY 2020.

More reading

• Sonic Healthcare share price pushes higher on FY 2020 guidance update
• Coronavirus second wave potential could drive investment portfolio changes
• Best growth shares to buy with $4,000
• 5 things to watch on the ASX 200 on Wednesday
• Afterpay share price on watch after reaching 1 million UK customers

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of AFTERPAY T FPO and APA Group. The Motley Fool Australia has recommended Sonic Healthcare Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why Afterpay, APA, Evolution, & Sonic shares are storming higher appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/3fQL02L